27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
Japanese biotech PeptiDream has entered into a license and collaboration agreement with US RNAi therapeutics company Alnylam Pharmaceuticals to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver. 31 July 2021
Danish allergy immunotherapy specialist ALK Abello has announced an exclusive licensing agreement with China Grand Pharmaceutical and Healthcare Holdings (Grandpharma), that will see ALK’s adrenaline auto-injector (AAI) Jext registered and launched in China, and will expand ALK's presence in the country. 31 July 2021
US drugmaker AbbVie announced financial results for the second quarter of 2021, showing that revenues were up 33.9% on a reported basis at $13.959 billion, beating the expectations of analysts polled by FactSet of $13.63 billion. 30 July 2021
US biopharma Vertex Pharmaceuticals has raised full-year 2021 guidance for product revenues from $7.2 billion to $7.4 billion upon presenting its second-quarter financial results. 30 July 2021
US pharma major Eli Lilly’s Loxo Oncology unit has signed a multi-year collaboration with San Diego-based Kumquat Biosciences on the discovery, development and commercialization of potential novel small molecule that stimulate tumor-specific immune responses. 30 July 2021
Japanese drugmaker Takeda closed 2% down after Tokyo’s trading day on Friday, having presented its financial results from the first quarter, under Japan’s April to March financial year. 30 July 2021
The UK genomics sector has released a report detailing the strength of research in this area, highlighting what it sees as a broad range of investment opportunities. 30 July 2021
The UK’s Competition and Markets Authority (CMA) has imposed over £100 million ($139 million) in fines after Advanz inflated the price of thyroid tablets, causing the National Health Service (NHS) and patients to lose out. 30 July 2021
Shares in Californian kidney specialist Ardelyx are up a quarter in pre-market trading, despite the firm receiving a Complete Response Letter (CRL) for its candidate tenapanor. 30 July 2021
The US Food and Drug Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). 30 July 2021
Johnson & Johnson’s partner for manufacturing its coronavirus vaccine, Emergent BioSolutions, has announced it will be able to resume operations at its plant in Bayview, USA. 30 July 2021
US biotech major Gilead Sciences yesterday posting financials for second-quarter 2021, showing that revenues of $6.2 billion increased 21% compared to the same period in 2020. 30 July 2021
Japan’s Takeda Pharmaceutical and Frazier Healthcare Partners yesterday announced a collaboration to launch HilleVax, a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. 30 July 2021
US biotech Arrowhead Pharmaceuticals today announced that it was granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration for ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference (RNAi) therapeutic. 29 July 2021
New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had previously taken. 29 July 2021
Japan’s largest drugmaker Takeda Pharmaceutical says that the US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) to TAK-994, its Phase II investiga00tional oral orexin agonist, which is designed to selectively target orexin 2 receptors. 29 July 2021
Belgian largest drugmaker UCB today reported financial results for the first half of 2021, which saw the firm’s shares gain 1.8% to 91.98 euros by late afternoon. 29 July 2021
British drugmaker AstraZeneca delivered strong revenue growth in the second quarter, taking in $8.2 billion, an increase of 31% from the same period last year. 29 July 2021